Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so. You should be careful to avoid catching falling knives.Let's consider two stocks that have significantly lagged the market in recent years but could still fall further: Canopy Growth (CGC -5.95%) and Novavax (NVAX 0.92%). 1. Canopy GrowthCanopy Growth emerged as a leader in the cannabis industry toward the end o ...

In Canine Influenza Virus (CIV) studies, TruCan Ultra CIV was shown to be highly effective in protecting dogs' lungs and improving clinical signs: "With the recent USDA approval for TruCan Ultra CIV, Elanco continues to lead the charge in innovative animal health solutions," said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. "This vaccine not only offers broad protection against canine influenza but also integrates seamlessly into our Tru Portfolio. Our commitment ...

William Blair 45th Annual Growth Stock Conference Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases June 2025 Nasdaq: DVAX Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Dynavax's expected financial results and market share as of and for the quarter ended M ...

T h e C i t i z e n s L i f e S c i e n c e s C o n f e r e n c e R e d e f i n i n g t h e F u t u r e o f I m m u n i z a t i o n s Steven Lo Chief Executive Officer James F. Cummings, M.D. Chief Medical Officer May 7, 2025 Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, resu ...

Core Viewpoint - Hepion Pharmaceuticals has successfully transitioned to the OTCQB Venture Market, with its common stock trading under the symbol HEPA starting June 25, 2025 [1]. Company Overview - Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing diagnostic tests for various conditions, including celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori), and hepatocellular carcinoma (HCC) [2].

Core Insights - Cidara Therapeutics, Inc. (CDTX) stock surged over 90% following the release of positive topline results from its Phase 2b NAVIGATE trial for CD388, aimed at preventing seasonal influenza in healthy unvaccinated adults aged 18 to 64 [1][6] Study Results - The NAVIGATE trial met its primary endpoint, showing statistically significant prevention efficacy (PE) across all three dose groups, with evaluations conducted over 24 weeks [2] - The highest dose group (450 mg) achieved a 76.1% prevention efficacy, while the 300 mg and 150 mg doses demonstrated 61.3% and 57.7% efficacy, respectively, all statistically significant compared to placebo [3] - Secondary endpoints were also met, including efficacy at specific temperature thresholds and maintenance of PE for up to 28 weeks [2] Safety and Tolerability - CD388 was well-tolerated across all doses, with no unexpected dose-limiting treatment-emergent adverse events reported [3][4] - No serious drug-related adverse events were observed, and injection site reaction rates were consistent across all dose groups [4] Regulatory Actions - Cidara has submitted a request to the FDA for an end of Phase 2 meeting to discuss the results and the design of the upcoming Phase 3 trial [5]

Core Insights - Novavax announced positive results from a late-stage study of its COVID-19-influenza combination (CIC) and standalone influenza vaccine candidates, showing robust immune responses in adults aged 65 and older [1][2][8] - The study's findings will guide the design of another late-stage trial that could support regulatory submissions if successful [3][8] - Novavax is seeking strategic collaborations to finance further development and commercialization of both vaccine candidates as part of a strategic shift to expand its pipeline [4][8] Stock Performance - Novavax shares have underperformed the industry year to date [5] Recent Developments - The announcement followed the FDA's approval of Nuvaxovid for older adults, with a narrower label than expected, restricting use in individuals aged 12-64 with high-risk conditions [7][8] - Sanofi has acquired exclusive global marketing rights for Nuvaxovid, part of a multi-billion-dollar deal, and will receive tiered royalties on future sales [10] Competitive Landscape - Other companies like Pfizer and Moderna are also developing COVID-flu combination vaccines, with Moderna ahead in its investigational candidate mRNA-1083, despite a recent setback [11][12] - Pfizer faced challenges in its phase III study for its combination vaccine, missing one of its primary immunogenicity objectives [13] - Sanofi is testing multiple COVID-19/flu combination vaccine candidates, with two receiving fast-track designation from the FDA [14]

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate strategy and ...

Core Viewpoint - Novavax, Inc. announced positive results from the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) Phase 3 trial, indicating that both vaccine candidates induced immune responses comparable to licensed vaccines Nuvaxovid® and Fluzone HD [1][2][3] Group 1: Trial Results - The Phase 3 trial involved approximately 2,000 adults aged 65 and older, focusing on the safety and immunogenicity of the CIC and tNIV compared to Nuvaxovid and Fluzone HD [3] - Both vaccine candidates demonstrated robust immune responses, with neutralizing antibody responses increasing by 2.4 to 5.7 times over baseline [2][6] - The trial results showed that nearly all solicited adverse events (>98%) were mild or moderate, indicating good tolerability [2][6] Group 2: Future Development - The data from this trial will inform future discussions with potential partners regarding the registrational Phase 3 program for the CIC and tNIV vaccines [2][3] - Novavax continues to seek partnerships to advance the development of these vaccine programs [6]

Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” OR “Vaxart”) today announces a video update for stockholders by Dr. Sean Tucker. The video is available on Vaxart’s investor relations website at investors.vaxart.com. ...